首页 > 市场调查报告书 > 製药

神经疾病疼痛

市场调查报告书

商品编码

1491728

神经病变疼痛市场规模、份额、成长分析、按类型、按药物类别、按分销管道、按诊断/治疗、按最终用户 - 行业预测，2024-2031 年

Neuropathic Pain Market Size, Share, Growth Analysis, By Type, By Drug Class, By Distribution Channel, By Diagnosis & Treatment, By End User - Industry Forecast 2024-2031

出版日期: 2024年06月03日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球神经病变疼痛市场规模为25.1亿美元，从2023年的26.3亿美元成长到2031年的38亿美元，预测期（2024-2031）预计复合年增长率为4.72%。

神经病变疼痛是由影响体感神经系统的损伤或疾病引起的，引起称为感觉异常的异常感觉和通常非疼痛刺激引起的疼痛。它可以表现为持续的不适或阵发性的感觉，如刺痛或电击，通常是由神经系统损伤或功能障碍引起的。这种神经损伤会导致局部和周围部位的神经功能改变。神经病变疼痛的一个突出例子是幻肢综合症。幻肢综合症是一种罕见的疾病，患者的手臂或腿因疾病或受伤而被截肢，但大脑继续接收最初与缺失肢体相连的神经的疼痛信号。这些不正确的神经讯号会导致持续疼痛。全球神经病变疼痛市场按药物类别、适应症、分销管道和地区细分。药物类别包括三环抗忧郁药物、鸦片类药物、辣椒素乳膏和类固醇。适应症包括糖尿病神经病变、脊椎狭窄和化疗引起的周边神经病变。销售管道有零售药局、医院药局、网路药局。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

Grunenthal GmbH（Germany）
Mallinckrodt Pharmaceuticals（United States）
Pfizer Inc.（United States）
Novartis AG（Switzerland）
Teva Pharmaceutical Industries Ltd.（Israel）
GlaxoSmithKline plc（GSK）（United Kingdom）
Cipla Inc.（InvaGen Pharmaceuticals Inc.）（India）
Glenmark Pharmaceuticals（India）
Centaur Pharmaceuticals（India）
Sun Pharmaceutical Industries Ltd.（India）
Dr. Reddy's Laboratories Ltd.（India）
Lupin Ltd.（India）
Laurus Labs（India）
Lannett Company, Inc.（United States）
Astellas Pharma Inc.（Japan）
Biogen Inc.（United States）
Cirtec Medical Corporation（United States）
Integer Holdings Corporation（United States）
B. Braun SE（Germany）
Medtronic plc（Ireland）

简介目录

Product Code: SQMIG35D2215

Global neuropathic pain market size was valued at USD 2.51 billion in 2022 and is poised to grow from USD 2.63 billion in 2023 to USD 3.80 billion by 2031, growing at a CAGR of 4.72% in the forecast period (2024-2031).

Neuropathic pain stems from damage or illness affecting the somatosensory nervous system, leading to abnormal sensations known as dysesthesia or pain triggered by typically non-painful stimuli. It may manifest as continuous discomfort or episodic sensations akin to stabbings or electric shocks, often resulting from nerve damage or dysfunction within the nervous system. Such nerve damage can induce alterations in nerve function both locally and in surrounding areas. A notable example of neuropathic pain is phantom limb syndrome, a rare condition occurring when an arm or leg is amputated due to illness or injury, yet the brain continues to receive pain signals from the nerves originally connected to the missing limb. These errant nerve signals contribute to persistent pain. The global neuropathic pain market is segmented by drug class, indication, distribution channel, and region. Drug classes include tricyclic antidepressants, opioids, capsaicin cream, and steroids. Indications encompass diabetic neuropathy, spinal stenosis, and chemotherapy-induced peripheral neuropathy. Distribution channels consist of retail pharmacies, hospital pharmacies, and online pharmacies.

Top-down and bottom-up approaches were used to estimate and validate the size of the neuropathic pain market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Neuropathic Pain Market Segmental Analysis

The neuropathic pain market is segmented based on indication, drug class, end user, type, diagnosis & treatment, distribution channel, and region. By indication, the market is segmented into diabetic neuropathy, spinal stenosis, chemotherapy-induced peripheral neuropathy, and others. By drug class, the market is segmented into tricyclic antidepressants, opioids, capsaicin cream, steroids, and others. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, drug stores, and others. Based on type, the market is segmented into peripheral neuropathy, entrapment neuropathy, post traumatic, neuropathy, phantom limb pain, post herpetic neuralgia (PHN), trigeminal neuralgia, others. Based on diagnosis & treatment, the market is segmented into imaging, blood tests, physical examination, medication, multimodal therapy, and others. Based on end user, the market is segmented into hospitals, clinics, research organizations, and others. By region, the market is segmented into North America, Europe, Asia-Pacific, Middle East, and Africa, and Latin America.

Drivers of the Neuropathic Pain Market

The escalating occurrence of chronic conditions like diabetes, cancer, and multiple sclerosis, combined with an aging populace, has resulted in a heightened prevalence of neuropathic pain. This expanding patient demographic propels the need for efficient pain management interventions, thereby fostering the growth of the neuropathic pain market.

Restraints in the Neuropathic Pain Market

Managing neuropathic pain can present significant challenges, and conventional treatments may occasionally offer limited effectiveness in delivering comprehensive pain relief. This shortfall can affect patient satisfaction and potentially impede market expansion if alternative treatment avenues are not readily accessible.

Market Trends of the Neuropathic Pain Market

Sedentary and unhealthy lifestyles play significant roles in the widespread prevalence of diabetes globally. For example, according to the updated article titled "Epidemiology and classification of diabetic neuropathy" from January 2021, diabetic polyneuropathy stands as the most prevalent neuropathy in developed nations. The article also indicates that around 50% of individuals with diabetes will eventually experience neuropathy. These findings, illustrating the likelihood of neuropathy occurrence among diabetic patients, underscore the increasing burden of this condition. Consequently, this market segment is anticipated to exhibit growth over the forecast period.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Pricing Analysis
Start Up Analysis
Regulatory Landscape
Patent Analysis
Pipeline Analysis
Key Success Factors
Market Attractiveness Index
Degree of Competition
Top Investment Pockets
Ecosystem Mapping

Neuropathic Pain Market by Type

Market Overview
Peripheral Neuropathy
Entrapment Neuropathy
Post Traumatic
Neuropathy
Phantom Limb Pain
Post Herpetic Neuralgia (PHN)
Trigeminal Neuralgia
Others

Neuropathic Pain Market by Indication

Market Overview
Diabetic Neuropathy
Spinal Stenosis
Chemotherapy
Induced Peripheral Neuropathy

Neuropathic Pain Market by Diagnosis & Treatment

Market Overview
Imaging
Blood Tests
Physical Examination
Medication
Multimodal Therapy
Others

Neuropathic Pain Market by Drug Class

Market Overview
Tricyclic Antidepressants
Opioids
Capsaicin Cream
Steroids

Neuropathic Pain Market by Distribution Channel

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Drug Stores
Others

Neuropathic Pain Market by End User

Market Overview
Hospitals
Clinics
Research Organizations
Others

Neuropathic Pain Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Grunenthal GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mallinckrodt Pharmaceuticals (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (GSK) (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Inc. (InvaGen Pharmaceuticals Inc.) (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Glenmark Pharmaceuticals (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Centaur Pharmaceuticals (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Laurus Labs (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lannett Company, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cirtec Medical Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Integer Holdings Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
B. Braun SE (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medtronic plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments